STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma

The purpose of this study is to compare the effects on participants' and liver cancer by adding a drug that is used on its own to treat this disease to a combination of two other drugs which is also used to treat liver cancer, compared to the two-drug combination alone.

Trial Details

NCT ID
NCT06880523
Phase
PHASE2
Sponsor
Canadian Cancer Trials Group
Status
RECRUITING
Cancer Type
Hepatocellular Carcinoma (HCC) Liver Cancer
Interventions
  • STRIDE (durvalumab + tremelimumab)
  • Durvalumab
  • Lenvatinib
Locations (sample)
  • Calgary, Alberta, Canada|51.05011,-114.08529
  • Vancouver, British Columbia, Canada|49.24966,-123.11934
  • Hamilton, Ontario, Canada|43.25011,-79.84963
  • Kingston, Ontario, Canada|44.22976,-76.48098
  • Kitchener, Ontario, Canada|43.42537,-80.5112

Key Eligibility Criteria

  • Age ≥ 18 years.
  • Body weight \> 30 kg.
  • Life expectancy of at least 12 weeks.
  • Confirmed HCC based on histopathological findings from tumour tissues or clinically by AASLD criteria in cirrhotic participants.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hepatocellular Carcinoma (HCC) Liver Cancer Trials on Trialify →